Viewing Study NCT06293664



Ignite Creation Date: 2024-05-06 @ 8:12 PM
Last Modification Date: 2024-10-26 @ 3:22 PM
Study NCT ID: NCT06293664
Status: RECRUITING
Last Update Posted: 2024-03-05
First Post: 2024-02-28

Brief Title: Protocol for Alpha MSH Infusion Study in Patients With Type 2 Diabetes
Sponsor: Dasman Diabetes Institute
Organization: Dasman Diabetes Institute

Study Overview

Official Title: Randomized Cross-over Designed Study of the Physiological Impact of Alpha MSH on Glycemic Response to an Oral Glucose Tolerance Test in Patients With Type 2 Diabetes
Status: RECRUITING
Status Verified Date: 2024-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: α-MSH T2DM
Brief Summary: Alpha-melanocyte stimulatory hormone α-MSH is a melanocyte-stimulating hormone produced by the hypothalamus and released from the pituitary gland It acts as an agonist to the melanocortin 5 receptor MC5R in human skeletal muscle playing a role in glucose uptake and disposal This study aims to investigate whether α-MSH can enhance glucose tolerance in patients with Type 2 Diabetes Mellitus T2DM
Detailed Description: Pre-clinical studies in mice have shown improved glucose clearance with α-MSH infusion particularly in skeletal muscle Research has demonstrated that α-MSH improves glucose tolerance in healthy humans by promoting glucose uptake in skeletal muscle cells

Therefore this study seeks to answer the question of whether alpha-MSH improves glucose tolerance in patients with T2DM This will be addressed through measuring the impact of α-MSH infusion in patients with T2DM The research involves a double-blinded randomized placebo-controlled crossover study

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None